Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28087397 | 1.00 | TAAR1 (0.57) | TAAR1GAAKMT2AMEN1CA12 | |
| Hydrochloric Acid SCHEMBL28087267 | 0.98 | TAAR1 (0.55) | TAAR1GAAKMT2AMEN1CA12 | |
| Hydrochloric Acid SCHEMBL174859 | 0.98 | TAAR1 (0.55) | TAAR1GAAKMT2AMEN1CA12 | |
| Oxalic Acid SCHEMBL27962691 | 0.90 | GAA (0.52) | TAAR1GAAKMT2AMEN1CYP1A2 | |
| SCHEMBL13801229 | 0.89 | TAAR1 (0.53) | TAAR1GAAKMT2AMEN1CA12 | |
| SCHEMBL13644447 | 0.89 | TAAR1 (0.57) | TAAR1GAAKMT2AMEN1CA12 | |
| SCHEMBL12574171 | 0.85 | TAAR1 (0.53) | TAAR1GAAKMT2AMEN1CA12 | |
| SCHEMBL937041 | 0.85 | TAAR1 (0.53) | TAAR1GAAKMT2AMEN1CYP1A2 | |
| SCHEMBL23374696 | 0.84 | TAAR1 (0.52) | TAAR1GAAKMT2AMEN1CA12 | |
| Hydrochloric Acid SCHEMBL3770898 | 0.84 | TAAR1 (0.52) | TAAR1GAAKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210625-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. | 2015-07-30 | — | — | US | claimed |
| US-8952197-B2 | Processes for the preparation of 5-HT2C receptor agonists | ARENA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20120142967-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | claimed |
| EP-2443080-A2 | PROCESS FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2010148207-A2 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | claimed |
| CN-106031712-B | Lorcaserin hydrochloride pellet, preparation method and preparation thereof | 谢斌 | 2020-05-05 | — | — | CN | disclosed |
| US-10308611-B2 | Process for the preparation of Lorcaserin hydrochloride | AUROBINDO PHARMA LTD (IN) | 2019-06-04 | — | — | US | disclosed |
| US-20180194734-A1 | A process for the preparation of Lorcaserin Hydrochloride | AUROBINDO PHARMA LTD (IN) | 2018-07-12 | — | — | US | disclosed |
| CN-107669687-A | 5 HT for body weight control2CThe modified release dosage form of activator | 艾尼纳制药公司 | 2018-02-09 | — | — | CN | disclosed |
| US-9714225-B2 | Processes for the preparation of lorcaserin | CADILA HEALTHCARE LIMITED (IN) | 2017-07-25 | — | — | US | disclosed |
| US-9714225-B2 | Processes for the preparation of lorcaserin | CADILA HEALTHCARE LIMITED (IN) | 2017-07-25 | — | — | US | disclosed |
| US-20160280658-A1 | PROCESSES FOR THE PREPARATION OF LORCASERIN | CADILA HEALTHCARE LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| WO-2009111004-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES RELATED TO THE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | ARENA PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
| WO-2008070111-A2 | PROCESSES FOR PREPARING (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070111-A2 | PROCESSES FOR PREPARING (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080045502-A1 | Processes for Preparing 3-Benzazepines | ARENA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045502-A1 | Processes for Preparing 3-Benzazepines | ARENA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007120517-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280658-A1 | PROCESSES FOR THE PREPARATION OF LORCASERIN | CEL, CMA1, NISCH | TAAR1 435/4885GAA 56/4885KMT2A 1745/4885 |
| US-20120142967-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR3C, HTR5A | TAAR1 155/4885GAA 2690/4885KMT2A 652/4885 |
| US-10308611-B2 | Process for the preparation of Lorcaserin hydrochloride | CEL, LIPA, CMA1 | TAAR1 976/4885GAA 44/4885KMT2A 1704/4885 |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | HTR2C, HTR3C, HTR1A | TAAR1 203/4885GAA 2708/4885KMT2A 820/4885 |
| US-20180194734-A1 | A process for the preparation of Lorcaserin Hydrochloride | CMA1, HTR1F, HTR1A | TAAR1 601/4885GAA 61/4885KMT2A 1387/4885 |
| US-20150210625-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR3C, HTR5A | TAAR1 155/4885GAA 2690/4885KMT2A 652/4885 |
| US-20080045502-A1 | Processes for Preparing 3-Benzazepines | HTR3C, HTR3B, HTR3A | TAAR1 193/4885GAA 871/4885KMT2A 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.